<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614744</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0038</org_study_id>
    <secondary_id>U10HD036790</secondary_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD027871</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD053089</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>U10HD053119</secondary_id>
    <secondary_id>U10HD053124</secondary_id>
    <secondary_id>UL1RR024139</secondary_id>
    <secondary_id>UL1RR025744</secondary_id>
    <secondary_id>UL1RR024979</secondary_id>
    <secondary_id>U10HD068244</secondary_id>
    <secondary_id>1U10HD068263-01</secondary_id>
    <secondary_id>U10HD068270</secondary_id>
    <secondary_id>U10HD068278</secondary_id>
    <secondary_id>U10HD068284</secondary_id>
    <nct_id>NCT00614744</nct_id>
  </id_info>
  <brief_title>Late Hypothermia for Hypoxic-Ischemic Encephalopathy</brief_title>
  <official_title>Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled, clinical trial to evaluate whether induced
      whole-body hypothermia initiated between 6-24 hours of age and continued for 96 hours in
      infants ≥ 36 weeks gestational age with hypoxic-ischemic encephalopathy will reduce the
      incidence of death or disability at 18-22 months of age. The study will enroll 168 infants
      with signs of hypoxic-ischemic encephalopathy at 16 NICHD Neonatal Research Network sites,
      and randomly assign them to either receive hypothermia or participate in a non-cooled control
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE) is a rare, but life-threatening condition characterized
      by acute or subacute brain injury due to asphyxia. In most cases the underlying cause and
      timing of injury are unknown, but many cases are diagnosed at or shortly after birth.

      According to the World Health Organization, more than 722,000 children died from birth
      asphyxia and birth trauma worldwide in 2004. An estimated 50-75 percent of infants with
      severe (stage 3) HIE will die, with 55 percent of these deaths occurring in the first month.

      The incidence of long-term complications depends on the severity of HIE. Up to 80 percent of
      infants who survive stage 3 HIE develop significant long-term neurological disabilities -
      mental retardation, epilepsy, and cerebral palsy with hemiplegia, paraplegia, or
      quadriplegia; 10-20 percent develop moderately serious disabilities; and up to 10 percent are
      normal.

      Because animal data suggests that brain injury from HIE evolves over several hours to days
      after the initial asphyxic insult, induced hypothermia holds promise as a neuroprotective
      therapy. Additional trials are needed to help define the most effective cooling strategies.

      With this in mind, and knowing that many babies with HIE arrive at neonatal intensive care
      units several hours after birth, this study will evaluate the safety and efficacy of
      initiating hypothermia 6-24 hours after birth.

      Study subjects: Infants born at 36 0/7ths weeks or greater gestational age that have been
      diagnosed with neonatal depression, perinatal asphyxia, or encephalopathy. The goal is to
      enroll 168 subjects.

      Stratification: After informed consent is obtained, infants will be randomized to either a
      hypothermia arm (with a target esophageal temperature of 33.5°C) or a control arm (37.0°C)
      for 96 hours. Enrolled infants will be stratified by age of enrollment (≤ 12 and &gt; 12 hours)
      and stage of encephalopathy (moderate or severe).

      Informed Consent: Parents of eligible infants will be approached for consent to enroll in the
      study if the infant has a high probability of acute hemodynamic compromise, as defined above.
      Subsequent screening will determine whether the infant meets all inclusion criteria.

      Randomization: eligible and consented infants will be randomly assigned to either a
      hypothermia intervention group, or a non-cooled (control) group.

      Study Intervention: Induced whole-body hypothermia (with a target esophageal temperature of
      33.5°C) or a control group (37.0°C) for 96 hours.

      Interim Study Interruptions: None to date.

      Secondary Study includes determining an association between MRI detectable injury and
      neurodevelopment at 18-22 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Moderate or Severe Disability</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
    <description>Severe disability was defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths in the NICU and Following Discharge</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Moderate and Severe Disability</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
    <description>Moderate disability will be defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 or blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Mild, Moderate and Severe Disability</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
    <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2 OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
    <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Non-CNS Organ System Dysfunction</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
    <description>Based on observing presence of organ dysfunction on at least one of the following: Pulmonary (Meconium aspiration syndrome, PPHN, Pulmonary hemorrhage, Pneumonia, Chronic lung disease, ECMO, INO), Cardiovascular (Cardiomegaly, Cardiac failure, Cardiac dysfunction (by echo), Cardiac ischemia (by EKG and/or increased enzymes), Hypotension, Arrhythmia), Renal (Oliguria, Anuria, Dialysis), Gastrointestinal (NEC, Hepatic dysfunction), Hematologic (DIC) and Metabolic (Hypoglycemia, Hypocalcemia, Hypomagnesemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With a DNR Order</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With a DNR Order and Support is Withdrawn</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With a DNR Order That Died</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities</measure>
    <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Infant, Newborn</condition>
  <condition>Hypoxia, Brain</condition>
  <condition>Hypoxia-Ischemia, Brain</condition>
  <condition>Encephalopathy, Hypoxic-Ischemic</condition>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <condition>Ischemic-Hypoxic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Whole-body Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypothermia</intervention_name>
    <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
    <arm_group_label>Whole-body Hypothermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normothermic Control</intervention_name>
    <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
    <arm_group_label>Normothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born at 36 0/7ths weeks gestational age or greater (by best obstetrical
             estimate)

          -  Postnatal age between 6 and 24 hours following birth

          -  Infants with a high probability of acute hemodynamic compromise, such as those with:

               -  An acute perinatal event (abruptio placenta, cord prolapse, severe FHR
                  abnormality)

               -  An Apgar score ≤ 5 at 10 minutes

               -  Continued need for ventilation initiated at birth for at least 10 minutes

               -  Cord pH or first postnatal blood gas pH at ≤ 1 hour of ≤ 7.0

               -  Base deficit on cord gas or first postnatal blood gas at ≤ 1 hour of ≥ 16 mEq/L

          -  Infants matching the above criteria who also have an abnormal neurological exam
             showing the presence of moderate or severe encephalopathy

          -  Infants whose parents/legal guardians have provided consent for enrollment.

        NOTE: These inclusion criteria are identical to the NICHD Neonatal Research Network's 2005
        Hypothermia study (see links below), except for the time of entry (6-24 hours vs. &lt; 6 hours
        of age).

        Exclusion Criteria:

          -  Any infant with a core body temperature (axilla, rectal) less than 34.0°C for greater
             than 1 hour

          -  Presence of a known anomaly or chromosomal aberration

          -  Birth weight &lt; 1,800 grams

          -  Infant in extremis

          -  Infants whose parents/legal guardians or attending physician refuse consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abbot R. Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele C. Walsh, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald N. Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J. Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda B. Poindexter, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P. Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan D. Frantz III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A. Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F. Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L. Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myra Wyckoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A. Kennedy, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger G. Faix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard A. Ehrenkranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Truog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Schmidt, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl D'Angio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Sanchez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://neonatal.rti.org/</url>
    <description>NICHD Neonatal Research Network</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NICHD Neonatal Research Network</keyword>
  <keyword>Hypoxic-ischemic encephalopathy (HIE)</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Neonatal depression</keyword>
  <keyword>Perinatal asphyxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter randomized trial to evaluate whether induced hypothermia with body cooling initiated between 6-24 hours of age and continued for 96 hours in infants &gt;= 36 weeks gestation with hypoxic-ischemic encephalopathy will reduce the incidence of death or disability at 18 months of age. Eligible infants were enrolled from 05/06/08 to 07/12/14.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Whole-body Hypothermia</title>
          <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
        </group>
        <group group_id="P2">
          <title>Normothermia</title>
          <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete for Behavior Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Whole-body Hypothermia</title>
          <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
        </group>
        <group group_id="B2">
          <title>Normothermia</title>
          <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age at Randomization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;= 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of Encephalopathy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3379" spread="528"/>
                    <measurement group_id="B2" value="3303" spread="553"/>
                    <measurement group_id="B3" value="3340" spread="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="3"/>
                    <measurement group_id="B2" value="51" spread="3"/>
                    <measurement group_id="B3" value="51" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="2"/>
                    <measurement group_id="B2" value="39" spread="1"/>
                    <measurement group_id="B3" value="39" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Moderate or Severe Disability</title>
        <description>Severe disability was defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit.</description>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Moderate or Severe Disability</title>
          <description>Severe disability was defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit.</description>
          <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Whole-body Hypothermia vs. Normothermia (Normothermia is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This trial estimated the probability that the intervention has no effect on the outcome (or conversely, the probability that it does), given the data obtained in the trial and any prior evidence.</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>In log binomial models used Normal (0, sd=0.35) neutral prior in the log RR scale. Estimation used Normal weakly informative priors. Reported posterior medians &amp; 95% credible intervals for the RR above instead of confidence intervals.</estimate_desc>
            <other_analysis_desc>We fitted all Bayesian models via Markov chain Monte Carlo methods (MCMC) using JAGS (version 3.4) and OpenBUGS (3.2.3) in R (version 3.2.5). For each analysis we ran 3 MCMC chains with starting values randomly drawn from the estimated parameters from a frequentist log binomial model. A burn-in of 1,000 iterations was used, with sampling from a further 10,000 iterations for each chain. To monitor convergence, trace plots and the Gelman-Rubin convergence diagnostic (Rhat) were used for all parameters.
For all analyses, the trace plots show good mixing of the 3 chains with Rhat &lt; 1.01 for all parameters, indicating convergence.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths in the NICU and Following Discharge</title>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths in the NICU and Following Discharge</title>
          <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Moderate and Severe Disability</title>
        <description>Moderate disability will be defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 or blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Moderate and Severe Disability</title>
          <description>Moderate disability will be defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 or Gross Motor Functional (GMF) Level of 3-5 or blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
          <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Mild, Moderate and Severe Disability</title>
        <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2 OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Mild, Moderate and Severe Disability</title>
          <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2 OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
          <population>Does not include 9 lost to follow up and 2 infants without outcome for behavior issues</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization</title>
        <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization</title>
          <description>Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score &gt;= 85 and any of the following: presence of a GMF level 1 or 2OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score &lt; 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate encephalopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe encephalopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Non-CNS Organ System Dysfunction</title>
        <description>Based on observing presence of organ dysfunction on at least one of the following: Pulmonary (Meconium aspiration syndrome, PPHN, Pulmonary hemorrhage, Pneumonia, Chronic lung disease, ECMO, INO), Cardiovascular (Cardiomegaly, Cardiac failure, Cardiac dysfunction (by echo), Cardiac ischemia (by EKG and/or increased enzymes), Hypotension, Arrhythmia), Renal (Oliguria, Anuria, Dialysis), Gastrointestinal (NEC, Hepatic dysfunction), Hematologic (DIC) and Metabolic (Hypoglycemia, Hypocalcemia, Hypomagnesemia)</description>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Non-CNS Organ System Dysfunction</title>
          <description>Based on observing presence of organ dysfunction on at least one of the following: Pulmonary (Meconium aspiration syndrome, PPHN, Pulmonary hemorrhage, Pneumonia, Chronic lung disease, ECMO, INO), Cardiovascular (Cardiomegaly, Cardiac failure, Cardiac dysfunction (by echo), Cardiac ischemia (by EKG and/or increased enzymes), Hypotension, Arrhythmia), Renal (Oliguria, Anuria, Dialysis), Gastrointestinal (NEC, Hepatic dysfunction), Hematologic (DIC) and Metabolic (Hypoglycemia, Hypocalcemia, Hypomagnesemia)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With a DNR Order</title>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With a DNR Order</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With a DNR Order and Support is Withdrawn</title>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With a DNR Order and Support is Withdrawn</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With a DNR Order That Died</title>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <population>Only infants with DNR order</population>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With a DNR Order That Died</title>
          <population>Only infants with DNR order</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities</title>
        <time_frame>Birth to 18-22 months corrected gestational age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole-body Hypothermia</title>
            <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Normothermia</title>
            <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During study intervention period: 124 hours from baseline (time of insertion of esophageal probe).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Whole-body Hypothermia</title>
          <description>Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours</description>
        </group>
        <group group_id="E2">
          <title>Normothermia</title>
          <description>Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PPHN/Acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alteration of skin integrity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators must adhere to the Neonatal Research Network Publication policies.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abbot Laptook</name_or_title>
      <organization>Brown University, Women &amp; Infants Hospital of Rhode Island</organization>
      <phone>401-274-1122 ext 47421</phone>
      <email>alaptook@wihri.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

